Latest update to the Australian Immunisation Handbook

Respiratory syncytial virus

The respiratory syncytial virus (RSV) chapter has been updated to reflect the expansion of the national RSV program to include RSV vaccine Arexvy for older adults aged ≥75 years and Aboriginal and Torres Strait Islander adults aged ≥60 years. Other changes include clarification on timing of RSV-specific monoclonal antibodies in infants and co-administration in older adults. Updates were made to data on effectiveness and efficacy of Arexvy RSV vaccine in older adults. The RSV product administration errors table was updated